No Data
Express News | 1.824 billion yuan market cap restricted shares will be lifted today, with Deguan New Materials, jinling pharmaceutical, and Wangcheng technology leading the way in market value lifting.
Jinling Pharmaceutical: Report for the third quarter of 2024
Jinling Pharmaceutical (000919.SZ): Intends to acquire a portion of shares of Xingong Fund and equity of non-cash distribution of Xingong Fund.
Gelonghui, October 21st | Jinling Pharmaceutical (000919.SZ) announced that in order to build the company's global strategy of "medical and health care dual platform", improve the company's medical regional market layout, and address the competition between Nanjing NewVenture Investment Group Co., Ltd. (referred to as "NewVenture Group") controlling Nanjing Meishan Hospital Co., Ltd. (referred to as "Nanjing Meishan Hospital") and the company, the company plans to acquire 28.46% of the shares of the Nanjing NewVenture Medical Industry Investment Fund Partnership Enterprise (Limited Partnership) (referred to as "fund" or "NewVenture Fund") held by NewVenture Group for 164.7317 million yuan.
Jinling Pharmaceutical: 2024 Semi-Annual Report Summary
Jinling Pharmaceutical: Semi-Annual Report 2024
Jinling Pharmaceutical (000919.SZ) released its half-year performance, with a net income of 51.8188 million yuan, a decrease of 33.16%.
Jinling Pharmaceutical (000919.SZ) released its 2024 interim report, during the reporting period, the company achieved revenue...
No Data
No Data